Sign up to save your podcasts
Or
Share Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings.
Key topics included:
• The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib.
• Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management.
• Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation.
• The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting.
Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and send us your challenging cases for future discussions!
#CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive
View all episodes
By Oncology Brothers
4.8
4040 ratings
In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings.
Key topics included:
• The recent updates from the MonarchE and NATALEE trials, highlighting the approval of abemaciclib and ribociclib.
• Strategies for selecting the right adjuvant treatment for high-risk patients, including dosing considerations and side effect management.
• Insights into managing common toxicities associated with CDK4/6 inhibitors, such as diarrhea and QTc prolongation.
• The role of CDK4/6 inhibitors in patients with visceral involvement and the implications of using these therapies in the metastatic setting.
Whether you're a healthcare professional or someone interested in the latest advancements in breast cancer treatment, this episode provided valuable insights and expert opinions on navigating complex treatment decisions.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and send us your challenging cases for future discussions!
#CDK4/6i #BreastCancer #MonarchE #NATALEE #Abemaciclib #Ribociclib #OncologyBrothers #HRpositive
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
58 Listeners
Mayo Clinic Talks
297 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,357 Listeners
Core IM | Internal Medicine Podcast
1,142 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners